A detailed history of Two Sigma Investments, LP transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 264,870 shares of VTYX stock, worth $468,819. This represents 0.0% of its overall portfolio holdings.

Number of Shares
264,870
Previous 236,774 11.87%
Holding current value
$468,819
Previous $546,000 5.68%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.85 - $3.2 $51,977 - $89,907
28,096 Added 11.87%
264,870 $577,000
Q2 2024

Aug 14, 2024

BUY
$2.31 - $5.59 $344,591 - $833,882
149,174 Added 170.29%
236,774 $546,000
Q1 2024

May 15, 2024

SELL
$1.9 - $10.13 $1.98 Million - $10.5 Million
-1,040,938 Reduced 92.24%
87,600 $481,000
Q4 2023

Feb 14, 2024

BUY
$2.08 - $31.18 $2.25 Million - $33.8 Million
1,083,138 Added 2385.77%
1,128,538 $2.79 Million
Q3 2023

Nov 14, 2023

SELL
$29.8 - $40.3 $1.32 Million - $1.78 Million
-44,291 Reduced 49.38%
45,400 $1.58 Million
Q2 2023

Aug 14, 2023

BUY
$28.53 - $39.55 $1.44 Million - $1.99 Million
50,340 Added 127.93%
89,691 $2.94 Million
Q1 2023

May 15, 2023

SELL
$29.51 - $46.65 $1.09 Million - $1.72 Million
-36,818 Reduced 48.34%
39,351 $1.32 Million
Q4 2022

Feb 14, 2023

SELL
$24.16 - $36.38 $367,860 - $553,921
-15,226 Reduced 16.66%
76,169 $2.5 Million
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $1.16 Million - $3.54 Million
91,395 New
91,395 $3.19 Million
Q1 2022

May 16, 2022

SELL
$10.0 - $19.98 $107,600 - $214,984
-10,760 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$14.2 - $23.07 $152,792 - $248,233
10,760 New
10,760 $214,000

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $100M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.